Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
New approaches to the treatment of dense deposit disease Smith RJ; Alexander J; Barlow PN; Botto M; Cassavant TL; Cook HT; de Cordoba SR; Hageman GS; Jokiranta TS; Kimberling WJ; Lambris JD; Lanning LD; Levidiotis V; Licht C; Lutz HU; Meri S; Pickering MC; Quigg RJ; Rops AL; Salant DJ; Sethi S; Thurman JM; Tully HF; Tully SP; van der Vlag J; Walker PD; Wurzner R; Zipfel PFJ Am Soc Nephrol 2007[Sep]; 18 (9): 2447-56The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.|Animals[MESH]|Complement Pathway, Alternative[MESH]|Disease Models, Animal[MESH]|Disease Progression[MESH]|Glomerulonephritis, Membranoproliferative/diagnosis/genetics/physiopathology/*therapy[MESH]|Humans[MESH]|Kidney/pathology/physiopathology[MESH] |
